These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29085668)

  • 1. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
    Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
    J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
    Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
    Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
    Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
    Aro K; Pasanen A; Bützow R; Loukovaara M
    Gynecol Oncol; 2024 Oct; 189():9-15. PubMed ID: 38972089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
    Li M; Zhao L; Shen D; Li X; Wang J; Wei L
    Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group.
    Yoon H; Suh DH; Kim K; No JH; Kim YB; Kim H
    Gynecol Oncol; 2024 May; 184():132-138. PubMed ID: 38309030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
    Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
    Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
    [No Abstract]   [Full Text] [Related]  

  • 12. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
    Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
    J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparaginase-like protein 1 as a prognostic tissue biomarker in clinicopathologically and molecularly characterized endometrial cancer.
    Loukovaara MJ; Huvila JK; Pasanen AM; Bützow RC
    Eur J Obstet Gynecol Reprod Biol; 2024 Sep; 300():23-28. PubMed ID: 38972163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status.
    de Freitas D; Aguiar FN; Anton C; de Almeida DC; Bacchi CE; Carvalho JP; Carvalho FM
    Heliyon; 2023 Jun; 9(6):e17495. PubMed ID: 37408903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L1CAM: amending the "low-risk" category in endometrial carcinoma.
    Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
    Kommoss FK; Karnezis AN; Kommoss F; Talhouk A; Taran FA; Staebler A; Gilks CB; Huntsman DG; Krämer B; Brucker SY; McAlpine JN; Kommoss S
    Br J Cancer; 2018 Aug; 119(4):480-486. PubMed ID: 30050154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
    Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
    Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
    Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
    Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.
    Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN
    Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.